Imugene Limited (ASX:IMU), an immune-oncology company is pleased to announce that it has raised approximately $3.0m as part of the Company’s option plan which expired on 31st March 2017.
- The price for shares exercised under the option plan was 1.5 cents per share.
- The unlisted options are to be issued in recognition of the additional services he has performed which has been deemed far in excess of the usual services of a Non-Executive Director of a company with Imugene’s positioning together with additional services Dr. Axel Hoos continues to provide.
IMU’s CEO, Leslie Chong said today “we are pleased with the outcome of the options plan which further places Imugene in a solid position to continue the development of our Her-2 focused clinical candidate, HER-Vaxx, plus our broader mimotope platform and arginine modulator program.”
The Company are also delighted that three prominent existing shareholders, Private Portfolio Managers, Platinum Asset Management and Celtic Capital, have increased their investment in Imugene via their roles as underwriters to the plan,” said Ms Chong.